Ashley Huggler
Medical · Grand Rapids, MINPI 1811276694
Payments from drug & device makers
Across 194 payments — averaging $18.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$689
- GSK$377
- Lilly USA, LLC$356
- AstraZeneca$253
- Pfizer$237
- Boehringer Ingelheim$191
- plus $1K from 28 others
What the payments were for
- Food & beverage$3,502100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 41 | $689 |
| GSK | 24 | $377 |
| Lilly USA, LLC | 19 | $356 |
| AstraZeneca | 15 | $253 |
| Pfizer | 12 | $237 |
| Boehringer Ingelheim | 10 | $191 |
| Dexcom, Inc. | 7 | $135 |
| AbbVie | 7 | $122 |
| Astellas Pharma US Inc | 6 | $120 |
| Merck | 5 | $119 |
| Amgen | 6 | $118 |
| E.r. Squibb & Sons, L.L.C. | 6 | $112 |
| Johnson & Johnson | 4 | $79 |
| Corium, LLC | 3 | $54 |
| Eisai Inc. | 2 | $47 |
| Xeris Pharmaceuticals, Inc. | 2 | $46 |
| Radius Health, Inc. | 2 | $43 |
| Otsuka America Pharmaceutical, Inc. | 2 | $43 |
| Supernus Pharmaceuticals, Inc. | 3 | $40 |
| Paratek Pharmaceuticals, Inc. | 2 | $36 |
| Sanofi-aventis U.S. LLC | 2 | $35 |
| Bardy Diagnostics, Inc. | 2 | $32 |
| Exact Sciences | 1 | $24 |
| Teva Pharmaceuticals USA, Inc. | 1 | $23 |
| Sanofi Pasteur Inc. | 1 | $21 |
| Endo Pharmaceuticals Inc. | 1 | $19 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $19 |
| Bayer | 1 | $19 |
| Amarin Pharma, Inc. | 1 | $18 |
| Ironshore Pharmaceuticals Inc. | 1 | $17 |
| Baxter Healthcare | 1 | $15 |
| Alkermes, Inc. | 1 | $15 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $14 |
| LNHC, Inc | 1 | $14 |
How this compares
$3,502 in reported general payments places this provider in the 80th percentile of 755 medical providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 67 | $77,234 |
| EliquisApixaban | 68 | $67,791 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 62 | $40,078 |
| TrulicityDulaglutide | 27 | $33,112 |
| OzempicSemaglutide | 19 | $30,361 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 15 | $30,057 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 19 | $25,568 |
| FarxigaDapagliflozin Propanediol | 20 | $23,119 |
| MyrbetriqMirabegron | 31 | $15,108 |
| Atorvastatin Calcium | 404 | $7,625 |
| Humalog Kwikpen U-100Insulin Lispro | 13 | $6,716 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 12 | $6,306 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 23 | $5,177 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 26 | $4,815 |
| Levothyroxine Sodium | 198 | $4,374 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $356 | $110,34594 claims |
| PfizerEliquis, Abrysvo | $237 | $71,35679 claims |
| AstraZenecaBreztri Aerosphere, Farxiga | $253 | $63,19782 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Shingrix | $377 | $37,05054 claims |
| Novo NordiskOzempic | $689 | $30,36119 claims |
| Astellas Pharma US IncMyrbetriq | $120 | $15,10831 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 755 medical providers in Michigan.
Other medical in Grand Rapids
- Meredith KentGrand Rapids$192K
- David BarneyGrand Rapids$21K
- Nisha McKenzieGrand Rapids$19K
- Brenda WhartonGrand Rapids$11K
- Andra TalaskaGrand Rapids$11K
- Jennifer DykhouseGrand Rapids$8K
- Evan GerondaleGrand Rapids$7K
- Caleb YoungbloodBerkley$215K
- Steven StoneKalamazoo$200K
- Amber ShullNorton Shores$154K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.